GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

Teladoc

Just days after its IPO, GoodRx already has a valuation that rivals that of Teladoc Health. Can the fast-growing upstart leverage its popularity to become the new king of virtual healthcare?

Should Teladoc Be Worried About GoodRx?

GoodRx garnered a fair amount of investor interest when it went public this week, and there are several reasons to keep watching it.

Can This IPO Shake Up the Pharmaceutical Industry?

GoodRx is a distinctive IPO, combining strong growth with real earnings.

GoodRx Holdings: Great Numbers, Great Business?

The newly public company helps consumers save money on prescription drugs -- and that may lead to investors making money on the shares.

Can Investing in GoodRx Make You Rich?

GoodRx Holdings just posted a significant IPO showing, with shares soaring on their first day trading.

GoodRx Holdings: A Cure For The Woes Of Growth Investing

The shares of GoodRx Holdings Inc. (NASDAQ: GDRX) skyrocketed on the first day of trading at the Nasdaq Stock Market after its initial public offering on Wednesday.
 What Happened:  The digital healthcare platform priced 34.6 million shares at $33 each in the IPO — suggesting a raised amount above $1.1 billion.

Digital Healthcare Services Provider GoodRx Surges 53% On Trading Debut

The drug pricing company was valued above $19 billion on its first day on the market.

GoodRx IPO Shows Low Drug Prices Can Still Mean Big Money

CNBC's Jim Cramer said he believes in GoodRx's product and purpose, advising investors to take a small position in the company after its IPO.

Jim Cramer on GoodRx's IPO: Start buying if the stock pulls back a little

The new company makes money from its customers saving money.

Good News for GoodRx's IPO: Drug Prices Are Rising Fast

Shares of private equity-backed GoodRx Holdings surged 40 percent in their debut on the Nasdaq on Wednesday after the online prescription drug platform raised $1.14 billion in its initial public offering. The stock opened at $46, compared to the IPO price of $33 per share.

GoodRx shares jump 40 percent in Nasdaq debut after $1.1 billion IPO

GoodRx Holdings Inc. (NASDAQ: GDRX) entered the market with a bang on Wednesday. The company originally priced its 34.6 million share initial public offering at $33 apiece, above the expected price range of $24 to $28.

GoodRx Enters the Market With a Bang

The company has been consistently profitable since 2016.

GoodRx jumps 40% in market debut

Here's why investors are hesitant about the latest high-profle healthcare company to go public.

4 Reasons to Avoid the GoodRx IPO

GoodRx is successful, profitable, and going public on Wednesday.

If You Thought Snowflake's IPO Was Exciting, You'll Want To Watch This Healthcare Tech Stock

Prescription pricing platform GoodRx Holdings will hit the public markets this week.

News for GoodRx Holdings Stock (GDRX)